Koh Young Technology Inc., renowned for its 3D optical inspection technology, is venturing into the medical field with its groundbreaking neurosurgical robot, Kymero. The company plans to submit a premarket approval application to the US Food and Drug Administration (FDA) next week, with aspirations to launch in the US by the first half of 2025. This move is part of its strategy to penetrate the world’s largest medical robot market.
The Kymero robot features a unique optical sensor integrated into the surgery bed, enabling real-time tracking of the robot’s position and orientation. This innovation aims to reduce surgery times and minimize patient complications. Utilizing high-precision optical sensors for navigation, Kymero avoids direct contact with nerves and arteries, enhancing safety during complex brain surgeries.
Cho Chul bum, a neurosurgery professor at the Catholic University of Korea, praised Kymero for its superior image implementation capabilities in procedures involving CT and MRI scans. The robot is also capable of implanting deep-brain electrodes for Parkinson’s disease treatments.
Currently, Koh Young holds the title of the world’s leading producer of 3D solder paste inspection systems used in electronics manufacturing. Since 2011, the company has diversified into medical technology, with its robots already performing over 500 surgeries in major South Korean hospitals since 2020.
Looking ahead, Koh Young is not only focusing on neurosurgical applications but also developing a digital X-ray device to complement its robotic surgery systems. The company’s aggressive expansion into the medical robot sector underscores its commitment to innovation and global market penetration, leveraging its existing expertise in precision technology.
